Lunai Bioworks shares rise 22.22% in intraday after agreeing to acquire CNS drug assets from Clemann Group for $20 million.

Lunai Bioworks surged 22.22% in intraday trading, following the March 26, 2026, announcement of a $20 million strategic acquisition of Clemann Group's blood-brain barrier delivery technology and Alzheimer's drug assets at $1.50 per share to address key CNS development bottlenecks. The clinical-stage biotech firm, which operates through the RENB, BioSymetrics, and RENC divisions, specializes in AI-driven drug discovery, diagnostics, and bio-defense products.